Carlisle P S, Gucalp R, Wiernik P H
Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York.
Infect Control Hosp Epidemiol. 1993 Jun;14(6):320-4. doi: 10.1086/646750.
Identification of overall and site-specific rates of nosocomial infection in neutropenic patients with cancer and associated pathogens.
Cumulative continuous prospective surveillance over a 42-month period. Criteria and definitions of infection in neutropenic patients (absolute neutrophil counts < 1,000/mm3) were developed, and surveillance was carried out by a certified infection control nurse and a senior oncology research fellow.
A cancer research center with two designated oncology nursing units.
Neutropenic patients with hematological and solid malignancies undergoing high-dose chemotherapy with and without autologous bone marrow transplantation. All patients admitted to both of the units during the study period were surveyed. Those who developed neutropenia are included in this report.
A total of 444 nosocomial infections were identified in 920 neutropenic patients during 9,582 days of neutropenia for an overall rate of 48.3 per 100 neutropenic patients, or 46.3 per 1,000 days at risk. The rate of bloodstream infection per 100 neutropenic patients was 13.5 (gram-positive, 9.2; gram-negative, 4.8; and Candida 1.2). Other site-specific rates were: urinary tract, 5.7; respiratory tract, 5.5; thrush, 6.6; skin, 3.4; and gastrointestinal tract, 3.4. Among 392 pathogens identified, there were 137 (35%) gram-positive cocci, 105 (27%) gram-negative rods, 70 (18%) Candida, 37 (9%) gram-positive rods, 22 (6%) viruses, and 15 (4%) Aspergillus.
The rate of both overall and site-specific nosocomial infections in neutropenic patients is high. Neutropenia is a significant intrinsic risk factor that should be addressed in surveillance programs. Infection control and infectious diseases practitioners may need to modify techniques for surveillance, control, and management of infection in this population.
确定癌症中性粒细胞减少患者的医院感染总体发生率及特定部位发生率,并确定相关病原体。
在42个月期间进行累积连续性前瞻性监测。制定了中性粒细胞减少患者(绝对中性粒细胞计数<1000/mm³)感染的标准和定义,由一名经过认证的感染控制护士和一名资深肿瘤学研究员进行监测。
一个设有两个指定肿瘤护理单元的癌症研究中心。
接受高剂量化疗且有或无自体骨髓移植的血液系统和实体恶性肿瘤中性粒细胞减少患者。对研究期间入住两个单元的所有患者进行调查。发生中性粒细胞减少的患者纳入本报告。
在920例中性粒细胞减少患者的9582天中性粒细胞减少期内,共发现444例医院感染,总体发生率为每100例中性粒细胞减少患者48.3例,或每1000天风险期46.3例。每100例中性粒细胞减少患者的血流感染率为13.5(革兰阳性菌,9.2;革兰阴性菌,4.8;念珠菌,1.2)。其他特定部位感染率分别为:泌尿道,5.7;呼吸道,5.5;鹅口疮,6.6;皮肤,3.4;胃肠道,3.4。在鉴定出的392种病原体中,有137种(35%)革兰阳性球菌,105种(27%)革兰阴性杆菌,70种(18%)念珠菌,37种(9%)革兰阳性杆菌,22种(6%)病毒,15种(4%)曲霉菌。
中性粒细胞减少患者的医院感染总体发生率和特定部位发生率均较高。中性粒细胞减少是一个重要的内在风险因素,在监测计划中应予以关注。感染控制和传染病从业者可能需要调整该人群感染监测、控制和管理的技术。